Silintan is a dietary supplement marketed as a treatment for joint and body aches. According to a recent analysis by the FDA, however, all lots contained undeclared meloxicam, creating an increased risk of adverse events.
Financial literacy is no longer optional for physicians. “If you're not financially viable, you can't function,” explained Nirat Beohar, MD. “The business education is probably just as important as learning a new procedure.”
The ACC and AHA have published updated performance and quality measures focused on the diagnosis and management of peripheral artery disease. Several other specialty societies, including SCAI and SIR, also participated in the development of this new document.
The new policy applies to all health plans across Pennsylvania, New York, West Virginia and Delaware, “removing financial barriers for essential breast cancer diagnostics.”
The new deadline for the deal to be finalized is Dec. 31, 2025. However, the ultimate fate of UnitedHealth's acquisition of Amedisys will be decided in a federal court.
The new atrial shunt from Alleviant Medical was designed to treat heart failure without leaving a permanent implant behind. The FDA granted the technology its breakthrough device designation and approved additional research.
Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.
